06/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/15/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioCode SARS-CoV-2 Assay. The BioCode SARS-CoV-2 Assay is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
No hay comentarios:
Publicar un comentario